These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 32566906)

  • 41. Inhibiting Bacterial Drug Efflux Pumps via Phyto-Therapeutics to Combat Threatening Antimicrobial Resistance.
    Shriram V; Khare T; Bhagwat R; Shukla R; Kumar V
    Front Microbiol; 2018; 9():2990. PubMed ID: 30619113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and Syntheses of New Antibiotics Inspired by Nature's Quest for Iron in an Oxidative Climate.
    Miller MJ; Liu R
    Acc Chem Res; 2021 Apr; 54(7):1646-1661. PubMed ID: 33684288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Silver nanoparticles as antimicrobial therapeutics: current perspectives and future challenges.
    Prasher P; Singh M; Mudila H
    3 Biotech; 2018 Oct; 8(10):411. PubMed ID: 30237958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens.
    Baral B
    Front Pharmacol; 2023; 14():1036051. PubMed ID: 36762109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Next-Generation Drug Discovery to Combat Antimicrobial Resistance.
    Niu G; Li W
    Trends Biochem Sci; 2019 Nov; 44(11):961-972. PubMed ID: 31256981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
    Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
    ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nanomechanics of superbugs and superdrugs: new frontiers in nanomedicine.
    McKendry RA
    Biochem Soc Trans; 2012 Aug; 40(4):603-8. PubMed ID: 22817702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of environment on transmission of antibiotic-resistant superbugs in humans and strategies to lower dissemination of antibiotic resistance.
    K S; Vasanthrao R; Chattopadhyay I
    Folia Microbiol (Praha); 2023 Oct; 68(5):657-675. PubMed ID: 37589876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.
    Ayon NJ
    Metabolites; 2023 May; 13(5):. PubMed ID: 37233666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.
    Wang H; Chen D; Lu H
    Appl Microbiol Biotechnol; 2022 Jun; 106(11):3957-3972. PubMed ID: 35648146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors influencing inappropriate use of antibiotics: Findings from a nationwide survey of the general public in Malaysia.
    Wong LP; Alias H; Husin SA; Ali ZB; Sim B; Ponnampalavanar SSS
    PLoS One; 2021; 16(10):e0258698. PubMed ID: 34669733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibiotic resistance modifying ability of phytoextracts in anthrax biological agent Bacillus anthracis and emerging superbugs: a review of synergistic mechanisms.
    Dassanayake MK; Khoo TJ; An J
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):79. PubMed ID: 34856999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibacterial Properties and Efficacy of a Novel SPLUNC1-Derived Antimicrobial Peptide, α4-Short, in a Murine Model of Respiratory Infection.
    Jiang S; Deslouches B; Chen C; Di ME; Di YP
    mBio; 2019 Apr; 10(2):. PubMed ID: 30967458
    [TBL] [Abstract][Full Text] [Related]  

  • 55. WO
    Pramanik A; Dhar JA; Banerjee R; Davis M; Gates K; Nie J; Davis D; Han FX; Ray PC
    ACS Appl Bio Mater; 2023 Feb; 6(2):919-931. PubMed ID: 36746648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanotechnology: a contemporary therapeutic approach in combating infections from multidrug-resistant bacteria.
    Brar B; Marwaha S; Poonia AK; Koul B; Kajla S; Rajput VD
    Arch Microbiol; 2023 Jan; 205(2):62. PubMed ID: 36629918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens.
    Subramani R; Narayanasamy M; Feussner KD
    3 Biotech; 2017 Jul; 7(3):172. PubMed ID: 28660459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hybridization of antimicrobial oxazolidinones with commercial drugs: A fight against the "superbugs".
    Prasher P; Sharma M
    Drug Dev Res; 2023 Nov; 84(7):1337-1345. PubMed ID: 37583273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Opportunities for synthetic biology in antibiotics: expanding glycopeptide chemical diversity.
    Thaker MN; Wright GD
    ACS Synth Biol; 2015 Mar; 4(3):195-206. PubMed ID: 23654249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multitarget Approaches against Multiresistant Superbugs.
    Gray DA; Wenzel M
    ACS Infect Dis; 2020 Jun; 6(6):1346-1365. PubMed ID: 32156116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.